SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tunica Albuginea who wrote (4966)1/25/1998 10:55:00 AM
From: Bradpalm1  Read Replies (3) of 23519
 
Tunica,

Thankyou for your calm, reasoned response. I still disagree with you, however. The reason that the discussion of the effects of dipyramidole is very relevant here is that it happens to be a Type V-PDE inhibitor (like sildenafil) being currently used in clinical medicine (for details of it's Type V properties, see: J. Urol., 152:2159, 1994).

Further, for cardiac stress testing it's infused intravenously (0.14 mg/kg/min) over a 4- minute interval to achieve high serum concentrations in a subset of patients with known or probable atherosclerotic heart disease. This is the SAME subset of patients for whom the use of sildenafil is drawing so much concern. For now, until further is known about sidenafil, this is our best approximation of its possible adverse effects on this ED patient population.

Bradpalm1

P.S. GO DENVER --- I HATE THOSE PACKERS!!!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News